Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure
NCT ID: NCT02917031
Last Updated: 2021-11-08
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
348 participants
INTERVENTIONAL
2017-01-10
2019-08-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Saxagliptin
one tablet of saxagliptin 5 mg or 2.5 mg + one placebo capsule matching sitagliptin
Saxagliptin
5 mg or 2.5 mg, plain, yellow, biconvex, round, film-coated tablet
Placebo to match sitagliptin
50 mg or 100 mg, gray capsule
Sitagliptin
one capsule of sitagliptin 100 mg or 50 mg + one placebo tablet matching saxagliptin
Sitagliptin
50 mg or 100 mg, gray capsule
Placebo to match saxagliptin
2.5 mg or 5 mg, plain, yellow, biconvex, round, film-coated tablet
Placebo
one placebo tablet matching saxagliptin + one placebo capsule matching sitagliptin
Placebo to match saxagliptin
2.5 mg or 5 mg, plain, yellow, biconvex, round, film-coated tablet
Placebo to match sitagliptin
50 mg or 100 mg, gray capsule
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Saxagliptin
5 mg or 2.5 mg, plain, yellow, biconvex, round, film-coated tablet
Sitagliptin
50 mg or 100 mg, gray capsule
Placebo to match saxagliptin
2.5 mg or 5 mg, plain, yellow, biconvex, round, film-coated tablet
Placebo to match sitagliptin
50 mg or 100 mg, gray capsule
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Male or female, aged ≥18 years at the time of consent
3. Documented, controlled T2DM, as defined by:
* Diagnosis of Type 2 DM based on current ADA guidelines (Appendix C) Treatment with stable doses of antidiabetic medications that have not increased or decreased for ≥8 weeks before screening
* For patients taking insulin, the investigator must query the patient at prescreening or screening regarding his/her usual total daily insulin dose (all types combined) during the previous 8 weeks. Insulin dosages during pre-screening and screening should not vary by more than ±20% on more than two occasions
* Dosage reductions of insulin and sulfonylurea agents may be considered at randomization to minimize the possibility of hypoglycemia
* Any reductions in the dosage of insulin and sulfonylurea agents will be at the discretion of the investigator
* For patients treated with insulin, consider a reduction in dose of 20% at randomization
* For patients receiving sulfonylurea agents, consider a reduction in dose of 50% or discontinue if on a dosage that is considered low at randomization
4. HFrEF demonstrated by all 3 of the following criteria:
* History of HF and LVEF ≤45% within the last 6 months (echocardiogram, MRI, left ventriculography, or other accepted methodology). Patients without a recent assessment of LV function will undergo a local echocardiogram at the time of screening to determine ejection fraction
* Elevated NT-proBNP (\>300 pg/mL) during screening
* Patients should receive background standard of care for HFrEF and be treated according to locally recognized guidelines as appropriate. Guideline-recommended medications should be used at recommended doses unless contraindicated or not tolerated. Therapy should have been individually optimized and stable for \>or = 4 weeks (this does not apply to diuretics-see NB below) before screening visit and include (unless contraindicated or not tolerated):
* an ACE inhibitor, or ARB, or sacubitril/valsartan
* and
* a beta-blocker
* and
* if considered appropriate by the patient's treating physician; a mineralocorticoid receptor antagonist (MRA)
* NB: Most patients with heart failure require treatment with a diuretic to control sodium and water retention leading to volume overload. It is recognized that diuretic dosing may be titrated to symptoms, signs, weight, and other information and may thus vary. Each patient should, however, be treated with a diuretic regimen aimed at achieving optimal fluid/volume status for that individual
5. Stable HF, with no evidence of volume overload (no rales, jugular venous distention, peripheral edema) at screening
6. Women of childbearing potential (WOCBP):
* Must be using appropriate birth control to avoid pregnancy throughout the study and for up to 4 weeks after the last dose of investigational product
* Must have a negative serum or urine pregnancy test within 72 hours prior to the start of investigational product
* Must not be breastfeeding.
Exclusion Criteria
2. Patients with atrial fibrillation/flutter, or any rhythm that would impact on MRI imaging quality would be excluded. Patients with a prior history of atrial fibrillation or paroxysmal atrial fibrillation may be eligible for entry into the study based on the investigator's judgment related to the frequency of AF events and the patient's overall condition
3. Body mass index \>45 kg/m2 or any condition, including, but not limited to known claustrophobia, that may preclude the ability to perform an MRI scan of acceptable quality, or unwillingness to undergo MRI imaging
4. Receiving incretin therapy (DPP4 inhibitors, GLP-1 mimetics), or having received incretin therapy within the previous 8 weeks of randomization
5. Receiving therapy with a TZD or having received TZD therapy within the previous 8 weeks of randomization
6. Type 1 diabetes mellitus
7. History of unstable or rapidly progressing renal disease
8. A central lab eGFR value \<30 mL/min/1.73 m2 on pre-screening or screening
9. New York Heart Association (NYHA) Class IV HF
10. Myocardial infarction, stroke, transient ischemic attack, or coronary revascularization (percutaneous coronary intervention \[PCI\] or coronary artery bypass graft \[CABG\]) within the past 3 months of screening
11. Inoperable aortic or mitral valvular heart disease. Recent (within 3 months) or planned valvular heart procedure
12. Heart failure secondary to restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, and hypertrophic obstructive cardiomyopathy
13. Previous cardiac transplantation or transplantation indicated or expected within 6 months of randomization
14. Contraindications to saxagliptin therapy as outlined in the saxagliptin Investigator's Brochure, or to sitagliptin therapy as outlined in the sitagliptin prescribing information
15. Current treatment with strong cytochrome P450 (CYP) 3A4/5 inhibitors
16. Involvement in the planning and/or conduct of the study (applies to both AZ staff and/or staff at the study site)
17. Previous enrollment which disqualifies patient from re-enrollment based on the rules in Section 4.1 of the protocol, or previous randomization in the study
18. Participation in another clinical study with an investigational product during the last 30 days
19. Patients either employed by or immediate relatives of the Sponsor
20. Known human immunodeficiency virus (HIV) infection
21. Severe hepatic disease, including chronic active hepatitis. Positive serologic evidence of current infectious liver disease, including patients who are known to be positive for hepatitis B viral antibody IgM, hepatitis B surface antigen, or hepatitis C virus antibody; or aspartate transaminase (AST) or alanine transaminase (ALT) \>3X the upper limit of normal; or total bilirubin (TB) \>2 mg/dL
22. Active malignancy requiring treatment at the time of Visit 1(with the exception of successfully treated basal cell or treated squamous cell carcinoma).
23. Pregnant, positive pregnancy test, planning to become pregnant during clinical trial or breast feeding
24. History of any clinically significant disease or disorder which, in the opinion of the investigator, may put the patient at risk because of participation in the study, may influence the results, or may limit the patient's ability to participate in or complete the study
25. Unable or unwilling to provide written informed consent
18 Years
130 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Torrance, California, United States
Research Site
Upland, California, United States
Research Site
Miami, Florida, United States
Research Site
Ormond Beach, Florida, United States
Research Site
Chicago, Illinois, United States
Research Site
The Bronx, New York, United States
Research Site
The Bronx, New York, United States
Research Site
Sayre, Pennsylvania, United States
Research Site
Spartanburg, South Carolina, United States
Research Site
Houston, Texas, United States
Research Site
Milwaukee, Wisconsin, United States
Research Site
Sofia, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Chicoutimi, Quebec, Canada
Research Site
Santiago, , Chile
Research Site
Santiago, , Chile
Research Site
Santiago, , Chile
Research Site
Santiago, , Chile
Research Site
Talcahuano, , Chile
Research Site
Viña del Mar, , Chile
Research Site
Balatonfüred, , Hungary
Research Site
Budapest, , Hungary
Research Site
Budapest, , Hungary
Research Site
Budapest, , Hungary
Research Site
Debrecen, , Hungary
Research Site
Hajdúszoboszló, , Hungary
Research Site
Kecskemét, , Hungary
Research Site
Kisvárda, , Hungary
Research Site
Nyíregyháza, , Hungary
Research Site
Orosháza, , Hungary
Research Site
Pécs, , Hungary
Research Site
Székesfehérvár, , Hungary
Research Site
Brasov, , Romania
Research Site
Iași, , Romania
Research Site
Iași, , Romania
Research Site
Izhevsk, , Russia
Research Site
Kemerovo, , Russia
Research Site
Moscow, , Russia
Research Site
Moscow, , Russia
Research Site
Moscow, , Russia
Research Site
Nizhny Novgorod, , Russia
Research Site
Novosibirsk, , Russia
Research Site
Novosibirsk, , Russia
Research Site
Novosibirsk, , Russia
Research Site
Saint Petersburg, , Russia
Research Site
Saint Petersburg, , Russia
Research Site
Saint Petersburg, , Russia
Research Site
Tomsk, , Russia
Research Site
Tomsk, , Russia
Research Site
Yaroslavl, , Russia
Research Site
Busan, , South Korea
Research Site
Daejeon, , South Korea
Research Site
Gwangju, , South Korea
Research Site
Hwaseong-si, , South Korea
Research Site
Seongnam-si, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Seoul, , South Korea
Research Site
Wŏnju, , South Korea
Research Site
Bangkok, , Thailand
Research Site
Bangkok, , Thailand
Research Site
Bangkoknoi, , Thailand
Research Site
Chiang Mai, , Thailand
Research Site
Khon Kaen, , Thailand
Research Site
Ivano-Frankivsk, , Ukraine
Research Site
Ivano-Frankivsk, , Ukraine
Research Site
Kyiv, , Ukraine
Research Site
Kyiv, , Ukraine
Research Site
Kyiv, , Ukraine
Research Site
Lviv, , Ukraine
Research Site
Rivne, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kanie T, Mizuno A, Takaoka Y, Suzuki T, Yoneoka D, Nishikawa Y, Tam WWS, Morze J, Rynkiewicz A, Xin Y, Wu O, Providencia R, Kwong JS. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. Cochrane Database Syst Rev. 2021 Oct 25;10(10):CD013650. doi: 10.1002/14651858.CD013650.pub2.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D1680C00016
Identifier Type: -
Identifier Source: org_study_id